# PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects

> **NCT02130414** · PHASE1 · COMPLETED · sponsor: **Sigmoid Pharma** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Sandimmun® IV
- **DRUG:** CyCol® capsules

## Key facts

- **NCT ID:** NCT02130414
- **Lead sponsor:** Sigmoid Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02130414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02130414, "PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02130414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*